USMLE Forum Archives - USMLE Step 2 CK - ASTHAMA
ASTHAMA
sudha2015 - 01-13-11 10:05
Question: 1 A 52-week, randomized, open-label study by the P04139 Study Group evaluated the long-term use of mometasone furoate/formoterol (MF/F) in 404 patients with persistent asthma previously on medium-to high-dose inhaled corticosteroid (ICS). What was the primary endpoint of this study?
1.Asthma symptoms
2.Pulmonary function
3.Adverse events
4.Use of rescue medication
sudha2015 - 01-13-11 10:05
Question: 1 A 52-week, randomized, open-label study by the P04139 Study Group evaluated the long-term use of mometasone furoate/formoterol (MF/F) in 404 patients with persistent asthma previously on medium-to high-dose inhaled corticosteroid (ICS). What was the primary endpoint of this study?
1.Asthma symptoms
2.Pulmonary function
3.Adverse events
4.Use of rescue medication
Page 1
#2
Re: ASTHAMA
sudha2015 - 01-13-11 10:32 3.Adverse events
. The primary endpoint of this study was the number and percentage of patients reporting any adverse event. The incidence and rates of treatment-emergent adverse events were similar in patients receiving twice-daily doses of either MF/F or fluticasone propionate/salmeterol (FP/S), leading the authors to conclude that one-year treatment with twice-daily MF/F (200/10 or 400/10 micro gram) is safe and well tolerated in patients with persistent asthma.
#5
Re: ASTHAMA babbu5508 - 01-14-11 13:32 evaluated the long-term use of mometasone furoate/formoterol (MF/F) in 404 patients with persistent asthma previously on medium-to high-dose inhaled corticosteroid (ICS). What was the primary endpoint of this study?
3.Adverse events
Page 1